Quantitative analysis of ethical issues in phase I trials: A survey interview study of 144 advanced cancer patients

IRB Ethics and Human Research

Volumn 22, Issue 3, 2000, Pages

  Daugherty, Christopher K ^c   Banik, Donald M ^c   Janish, Linda ^c   Ratain, Mark J ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

ADULT; AGED; ARTICLE; BIOMEDICAL AND BEHAVIORAL RESEARCH; COMPREHENSION; DECISION MAKING; EMPIRICAL APPROACH; EVALUATION; HUMAN; HUMAN EXPERIMENT; INFORMATION PROCESSING; INFORMED CONSENT; INTERPERSONAL COMMUNICATION; MOTIVATION; NEOPLASM; PATIENT SATISFACTION; RESEARCH SUBJECT; RISK ASSESSMENT;

BIOMEDICAL AND BEHAVIORAL RESEARCH; EMPIRICAL APPROACH;

ADULT; AGED; COMPREHENSION; DATA COLLECTION; DECISION MAKING; DISCLOSURE; DRUGS, INVESTIGATIONAL; EVALUATION STUDIES; HUMANS; INFORMED CONSENT; MOTIVATION; NEOPLASMS; NONTHERAPEUTIC HUMAN EXPERIMENTATION; PATIENT SATISFACTION; RESEARCH SUBJECTS; RISK ASSESSMENT;

EID: 0034189187     PISSN: 01937758     EISSN: None     Source Type: Journal    
DOI: 10.2307/3564113     Document Type: Review

References (56)

1. Faden RR, Beauchamp TL, King NMP. A History and Theory of Informed Consent. New York, Oxford University Press, 1986.
2. Applebaum PS, Lidz CN, Meisel. A Informed Consent: Legal Theory and Clinical Practice. New York , Oxford University Press, 1987.
3. Levine RJ. Ethics and Regulation of Clinical Research, 2nd ed Baltimore, Md.: Urban and Schwarzenburg, 1986.
4. Daugherty CK, Ratain MJ, Siegler M. Ethical issues in the clinical research of cancer. In: Devita VT Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 5th ed. Philadelphia, J.P. Lippincott 1997: 534-542.
5. Pelligrino ED. Beneficence, scientific autonomy, and self-interest: Ethical dilemmas in clinical research. Cambridge Quarterly Health Ethics 1992; 1:361-69.
6. Levine RJ. Clinical trials and physicians as double agents. Yale Journal of Biology & Medicine 1992; 65:65-74.
7. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. United States Government Printing Office, Washington, D.C. 1978. Publication number (05) 78-0012.
8. Freedman B, Fuks A, Weijer C. Demarcating research in treatment: a systematic approach for the analysis of the ethics of clinical research. Clinical Research 1992; 40:655-60.
9. Bok S Shading the truth in informed consent for clinical research. Kennedy Institute Ethics Journal 1995; 5:1-17.
10. King NMP. Experimental treatment: oxymoron or aspiration? Hastings Center Report 1995; 25(4):6-15.
11. Ratain MJ, Mick R, Schilsky R, Siegler M. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. Journal of the National Cancer Institute 1993; 85:1637-43.
12. Lipsett MB. On the nature and ethics of phase I clinical trials. JAMA 1984; 248:941-2.
13. Storer B and DeMets D. Current phase I/II designs: are they adequate? Journal of Clinical Research Drug Development 1987; 1:121-30.
14. Freedman B. The ethical analysis of clinical trials: New lessons for and from cancer research. In: Vanderpool HY, ed The Ethics of Research Involving Human Subjects. Facing the 21st Century. Frederick, Md.: University Publishing Group 1996; 319-38.
15. Von Hoff DD, Turner J. Response rates, duration of response, and dose response effect in phase I studies in antineoplastics. Investigational New Drugs 1991; 9:115-22.
16. Decoster G, Stein G, Holdener EE. Responses and toxic deaths in phase I clinical trials. Annuals of Oncology 1990; 2:175-81.
17. Estey E, Hoth D, Wittes R, et al. Therapeutic responses in phase I trials of antineoplastic agents. Cancer Treatment Report 1986; 70:1105-15.
18. Smith TL, Lee JJ, Kantarjian HM, et al. Design and results of phase I cancer clinical trials: 3 year experience at MD Anderson Cancer Center. Journal of Clinical Oncology 1996; 14:287-95.
19. Daugherty CK, Ratain MJ, Grochowski E, et al. Perceptions of cancer patients and their physicians involved in phase I trials. Journal of Clinical Oncology 1995; 13:1062-72.
20. Collins JM, et al. Pharmacologically guided phase I clinical trials based upon preclinical drug development. Journal of the National Cancer Institute 1990; 82:1321-6.
21. DeVita VT. Principles of chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA eds. Cancer: Principles and Practice of Oncology, 4th ed. Philadelphia: JP Lippincott, 1997: 276-92.
22. Graham MA, et al. The impact of pharmacologically guided dose escalation strategies in phase I clinical trials: critical evaluation and recommendations for future studies. Annuals of Oncology 1992; 3:339-47.
23. Markman M. The ethical dilemma of phase I clinical trials. California Cancer Journal Clinical 1986; 36:367-9.
24. Sass HM. Ethical considerations in phase I clinical trials. Onkologie 1990; 13:85-8.
25. Hawkins MJ. Early cancer clinical trials: safety, numbers, and consent. Journal of the National Cancer Institute 1993; 85:1618-9.
26. Kent G. Shared understandings for informed consent: the relevance of psychological research on the provision of information. Social Science & Medicine 1996; 43:1517-24.
27. Verheggen FWSM, van Wijmen FCB. Informed consent in clinical trials. Health Policy 1996; 36:131-53.
28. Edwards SJL, Lilford RJ, Thornton J, et al. Informed consent for clinical trials: in search of the "best" method. Social Science & Medicine 1998; 47:1825-40.
29. Janisch L, Mick R, Schilsky RL, et al. Prognostic factors for survival in patients treated in phase I clinical trials. Cancer 74 1994; 1965-73.
30. Rodenhuis S, van-den Heuvel WJ, Annyas AA, et al. Patient motivation and informed consent in a phase I study of an anticancer agent. Europena Journal of Cancer & Clinical Oncology 1984; 20:457-62.
31. Tomamichel M, Sessa C, Herzig S, et al. Informed consent for phase I studies: evaluation of quantity and quality of information provided to patients. Annuals of Oncology 1995; 6:321-3.
32. Willem Y, Sessa C. Informing patients about phase I trials how should it be done? Aeta Oncology 1989; 28:106-7.
33. Yoder LH, O'Rourke TJ, Ethyre A, et al. Expectations and experiences of patients with cancer participating in phase I clinical trials. Oncology Nurses Forum 1997; 24:891-6.
34. Itoh K, Sasaki Y, Fuji H, et al. Patients in phase I trials of anti-cancer agents in Japan: motivation, comprehension and expectations. Brown Journal of Cancer 1997; 76:107-13.
35. Gray BH, Cooke RA, Tannebaum AS. Research involving human subjects. The performance of institutional review boards is assessed in this empirical study. Science 1978; 201:1094-1101.
36. Morrow GR. How readable are subject consent forms? JAMA 1990; 244:56-8.
37. Taub H, Baker M, Sturr H. Informed consent for research: affects of readability, patient age, and education. Journal of the American Geriatric Society 1986; 34:601-8.
38. White D, Muss H, Miechielutte R, et al. Informed consent: patient information forms in chemotherapy trials. American Journal of Clinical Oncology 1984; 7:183-190.
39. Loverde ME, Prochazka AV, Byyny RL. Research consent forms: continued unreadability and increasing length. Journal of General Internal Medicine 1989; 4:410-2.
40. Grossman SA, Piantadosi S, Covahey C. Are informed consent forms that describe clinical oncology research protocols readable by most patients and their families? Journal of Clinical Oncology 1994; 12:2211-5.
41. Jubelirer SJ. Level of reading difficulty in educational pamphlets and informed consent documents for cancer patients. West Virginia Medical Journal 1991; 87:554-7.
42. Tarnowski KJ, Allen DM, Mayhall C, et al. Readability of pediatric biomedical research informed consent forms. Pediatrics 1990; 85:58-62.
43. Lynoe N, Sandlund M, Dahlqvist G, et al. Informed consent: study of quality of information given to participants in a clinical trial. Brown Medical Journal 1991; 303:610-3.
44. Olver IN, Buchanan L, Ladlow C, et al. The adequacy of consent forms for informing patients enter-ing oncological clinical trials. Annuals of Oncology 1995; 6:867-70.
45. Sutherland HJ, Lockwood GA, Tritchler BL, et al. Communicating probabilistic information to cancer patients: is there "noise" on the line? Social Science & Medicine 1991; 32:725-31.
46. Llewellyn-Thomas H, McGreal MJ, Thiel EC. Patients' willingness to enter clinical trials: measuring the association with received benefit and preference for decision participation. Social Science & Medicine 1991; 32:35-42.
47. Simes RJ, Tattersal MHN, Coates AS, et al. Randomized comparison of procedures for obtaining informed consent in clinical trials of treatment for cancer. Brown Medical Journal 1986; 293:1065-8.
48. Searight HR, Miller CK. Remembering and interpreting informed consent: a qualitative study of drug trial participants. Journal of the American Board of Family Practice 1996; 9:14-22.
49. Davis TC, Holcombe RF, Berkel HJ, et al. Informed consent for clinical trials: a comparative study of standard versus simplified forms. Journal of the National Cancer Institute 1998; 90:668-74.
50. Schaeffer MH, Krantz DS, Wichman A, et al. The impact of disease severity on the informed consent process in clinical research. American Journal of Medicine 1996; 100:261-8.
51. Street RL. Information-giving in medical consultations: the influence of patients' communication styles and personal characteristics. Social Science & Medicine 1991; 32:541-8.
52. Mathews JJ. The communication process in clinical settings. Social Science & Medicine 1983; 17:1371-8.
53. Waitzkin H. Information giving in medical care. Journal of Health and Social Behavior 1985; 26:81-101.
54. Hall JB, Roter DL, Katz NR. Meta-analysis of correlates of provider behavior in medical encounters. Medical Care 1988; 26:657-73.
55. President's Advisory Committee. The Human Radiation Experiments. Oxford University Press; New York, 1996.
56. Daugherty CK, Ratain MJ, Minami H, et al. Study of cohort-specific consent and patient control in phase I cancer trials. Journal of Clinical Oncology 1998; 16:2305-12.